Bibliography
- WERNICKE JF: Safety and side effect profile of fluoxetine. Expert Opin. Drug Sal: (2004) 3(5):495–504.
- PRESKORN SH: How drug-drug interactions can impact managed care. Am. J. Manag. Care (2004) 10(6 Suppi.):5186–5198.
- ••SSRIs at used to illustrate thatdrug—drug interactionsdo have important Implications and adversely impact patient outcomes and have serious cost Implications.
- BROSEN K: Differences in interactions of SSRIs. Int. Clin. Psychopharmacol. (1998) 13\(Supp1.5):545–547.
- PRESKORN SH, BEBER JH, FAUL JC, HIRSCHFELD RM: Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am. Psychiatry (1990) 147(4):532.
- BROSEN K: The pharmacogenetics of the selective serotonin reuptake inhibitors. Investig. (1993) 71(12):1002–1009.
- ••An early review by a leading authority,stating unequivocally regarding fluoxetine: 'potent inhibitor of cytochrome P45 02D6 may cause serious interactions with tricyclic antidepressants and some neuroleptics'.
- CREWE HK, LENNARD MS, TUCKER GT, WOODS FR, HADDOCK RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. BE J. Pharmacol. (1992) 34(3):262–265.
- INGELMAN-SUNDBERG M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics (2005) 5(1):6–13.
- ••An authorative and complete overview of cytochrome P450 2D6.
- WEDLUND PJ, DE LEON J: Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin. Pharmacol. Ther. (2004) 75(5):373–375.
- •An editorial noting the critical importance that good observational research must play In confirming the clinical reality of P450 variations and drug—drug interactions.
- KIRCHHEINER J, NICKCHEN K, BAUER M et al: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry (2004) 9(5):442–473.
- PRESKORN SH: Drug-Drug Interactions: Proof of Relevance (Part I). Psychiatr. Pract. (2005) 11(2):116–122.
- ••An excellent recent paper covering most issues relating to drug—drug interactions involving psychotropic drugs.
- KELLY WN: Potential risks and prevention, Part 4: Reports of significant adverse drug events. Am. Health. Syst. Pharm. (2001) 58(15):1406–1412.
- ROBERTS RL, MULDER RT, JOYCE PR, LUTY SE, KENNEDY MA: No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum. Psychopharmacol. (2004) 19(1):17–23.
- GILLMAN PK: Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum. Psychopharmacol. (2004) 20(1):61–62.
- BEASLEY CM, MASICA DN, HEILIGENSTEIN JH, WHEADON DE, ZERBE RL: Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. I Clin. Psychopharmacol. (1993) 13:312–320.
- ••An important early report. It discusseseight cases of serotonin syndrome reported to Eli Lilly after a monoamine oxidase inhibitor was initiated concurrently with, or after, the discontinuation of fluoxetine. Seven had fatal outcomes, several some days after cessation of fluoxetine.
- POWER BM, PINDER M, HACKETT LP, ILETT KF: Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth. Intensive Care (1995) 23:499–502.
- BILBAO GARAY J, MESA PLAZA N, CASTILLA CASTELLANO V, DHIMES TEJADA P: Serotonin syndrome: report of a fatal case and review of the literature. Rev Clip. Esp. (2002) 202(4):209–211.
- ISBISTER GK, HACKETT LP, DAWSON AH, WHYTE IM, SMITH AJ: Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. BE J. Pharmacol. (2003) 56:441–450.
- ••The only systematic data, from a case seriesof 106 patients, on the extent of the risk of serotonin syndrome with modobemide and SSRIs (following overdose).
- GILLMAN PK: Serotonin syndrome: history and risk. Fundam. Clin. Pharmacol. (1998) 12(5):482–491.
- •The first analysis of the 'dose—effect' relationship and the relative risk of ST with different drugs and combinations.
- TIRKKONEN T, LAINE K: Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clip. Pharmacol. Ther. (2004) 76(6):639–647.
Websites
- www.fda.gov/cder/guidance/clin3.pdf Guidance for industry. Drug metabolism/drug interaction studies in the drug development process: studies hi vitro (1997).